pyrazines has been researched along with T-Cell Lymphoma in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biskup, E; Croce, CM; Gasparini, P; Gniadecki, R; Laganá, A; Manfè, V; Palmieri, D; Skov, AG; Willumsgaard, A; Woetmann, A; Ødum, N | 1 |
| Mangone, M; Marchi, E; O'Connor, OA; Zullo, K | 1 |
| Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L | 1 |
| Chen, L; Chen, Z; Gong, S; Guo, L; Lü, S; Wang, J; Yang, J; Zhou, H | 1 |
| Eom, HS; Huh, J; Kang, HJ; Kim, K; Kim, WS; Ko, YH; Lee, J; Park, K; Ryoo, BY; Suh, C | 1 |
| Chen, SJ; Chen, Z; Janin, A; Jiang, XX; Shen, ZX; Wang, L; Wu, WL; Yang, F; Zhang, QL; Zhang, YW; Zhao, WL | 1 |
| Chen, XY; Jiang, XX; Shen, ZX; Wu, WL; Zhang, QL; Zhao, WL | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, JM; Zinzani, PL | 1 |
| Chen, SJ; Janin, A; Jiang, XX; Leboeuf, C; Shi, WY; Wang, L; Xiao, D; Yang, F; Yao, Y; Zhao, WL | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Fujiwara, S; Gotoh, K; Isobe, Y; Ito, Y; Iwata, S; Kawada, J; Kimura, H; Nishiyama, Y; Sugimoto, K; Ushijima, Y; Yano, S | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Fu, K; Hao, XS; Ma, YL; Qian, ZZ; Wang, HQ | 1 |
| Arnulf, B; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Karam, JA; Kfoury, Y; Lepelletier, Y; Nasr, R | 1 |
| Jin, J; Mai, W; Meng, H; Wang, L | 1 |
| Au, WY; Guo, T; Kwong, YL; Liang, RH; Shen, L; Srivastava, G; Tsuchiyama, J; Wong, KY; Wong, ML; Yuen, PW | 1 |
| Alinari, L; Baccarani, M; de Vivo, A; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Sabattini, E; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Chen, SJ; Chen, Z; Garcia, JF; Janin, A; Leboeuf, C; Li, JM; Liu, YY; Ma, J; Shen, ZX; Song, YP; Wang, L; Zhang, QL; Zhang, YW; Zhao, WL | 1 |
| Bose, R; Cragoe, EJ; Greenberg, AH; Kraut, RP | 1 |
| Bennink, JR; Chen, W; Crews, CM; Myung, J; Princiotta, MF; Schubert, U; Yewdell, JW | 1 |
3 trial(s) available for pyrazines and T-Cell Lymphoma
| Article | Year |
|---|---|
Pralatrexate pharmacology and clinical development.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Proteasome Endopeptidase Complex; Pyrazines; Vincristine | 2008 |
Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Skin Neoplasms; Treatment Outcome | 2007 |
17 other study(ies) available for pyrazines and T-Cell Lymphoma
| Article | Year |
|---|---|
cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Boronic Acids; Bortezomib; Chromatin Immunoprecipitation; Computational Biology; DNA Primers; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Luciferases; Lymphoma, T-Cell; Mice; MicroRNAs; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Skin Neoplasms | 2013 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed | 2014 |
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Survival; Chymotrypsin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2008 |
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Protein Kinases; Pyrazines; Signal Transduction; Vorinostat; Xenograft Model Antitumor Assays | 2009 |
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Jurkat Cells; Lymphoma, T-Cell; Proteasome Inhibitors; Pyrazines | 2009 |
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
Topics: Aminopterin; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspase 9; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lymphoma, T-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Endothelial Cells; Enzyme Inhibitors; Humans; Jurkat Cells; Leukemia, T-Cell; Lymphoma, T-Cell; Mice; Mice, Nude; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Child; Enzyme Activation; Epstein-Barr Virus Infections; Female; Humans; Killer Cells, Natural; Lymphoma; Lymphoma, T-Cell; Male; NF-kappa B; Proteasome Inhibitors; Pyrazines; T-Lymphocytes | 2011 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
[In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Pyrazines | 2011 |
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Ceramides; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Synergism; Humans; Lymphoma, T-Cell; Male; Pyrazines; Radiography; Remission Induction | 2006 |
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Killer Cells, Natural; Leukemia, T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2007 |
PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Topics: Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; I-kappa B Proteins; Interferon Regulatory Factors; Lymphoma, T-Cell; Microdissection; Neoplasm Staging; NF-KappaB Inhibitor alpha; Positive Regulatory Domain I-Binding Factor 1; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Repressor Proteins; Survival Rate; Transcription Factors | 2008 |
Pyrazine compounds and the measurement of cytosolic Ca2+.
Topics: Aequorin; Calcium; Carrier Proteins; Cytosol; Fura-2; Lymphoma, T-Cell; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Pyrazines; Sodium; Sodium-Calcium Exchanger; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 1993 |
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.
Topics: Amino Acid Chloromethyl Ketones; Aminopeptidases; Animals; Antigen Presentation; Antigens; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Survival; Cysteine Endopeptidases; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Resistance; Endopeptidases; Enzyme Activation; H-2 Antigens; Leupeptins; Lymphoma, T-Cell; Mice; Multienzyme Complexes; Neoplasm Proteins; Oligopeptides; Peptide Fragments; Phenols; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Pyrazines; Selection, Genetic; Serine Endopeptidases; Sulfones; Thymus Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tyramine; Ubiquitins | 2001 |